6533b85dfe1ef96bd12be642

RESEARCH PRODUCT

Preliminary Results of Two Eortc Randomized Trials in Previously Untreated Patients with Advanced T3 — T4 Prostatic Cancer

Michele Pavone-macalusoRichard SylvesterStefan SuciuP. H. SmithM. De Pauw

subject

Oncologymedicine.medical_specialtybusiness.industryBone metastasisCyproterone acetateCancermedicine.diseaselaw.inventionCardiovascular deathchemistry.chemical_compoundchemistryRandomized controlled triallawInternal medicinemedicineMedroxyprogesterone acetateCooperative groupbusinessmedicine.drug

description

At the end of 1976 and the beginning of 1977 respectively, the EORTC Genito-Urinary Tract Cancer Cooperative Group started two randomized phase III protocols in previously untreated patients with advanced T3–4 prostatic cancer (1–3). The first trial, 30762, compared Stilboestrol and Estracyt, while the second, 30761, was a randomized comparison of Stilboestrol, Cyproterone Acetate and Medroxyprogesterone Acetate. Both trials have now been closed to patient entry and the principal endpoints of the studies analyzed. This paper will present the interim results which have emerged from these two studies.

yearjournalcountryeditionlanguage
1983-01-01
https://doi.org/10.1007/978-1-4684-4349-3_53